Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
February 26, 2020
November 22, 2019
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
November 7, 2019
Data from the PARTNER trials were assessed regarding post-procedural prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement and surgical aortic valve replacement. The timing and rates of PVE were similar between the groups, and they had a similar high mortality.
October 10, 2019
Reporting of postmarket outcomes for the Sapien 3 and Mitraclip devices frequently misclassified patient deaths as device malfunction or other outcomes. Misclassification for Sapien 3 involved 17.5% of patient deaths, and involved 24.7% of patient deaths for Mitraclip.
Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement
August 29, 2019
Using an approach that minimizes valve depth relative to the membranous septum, the authors reduced the need for permanent pacemaker placement to a reliable and predictable 3% compared to the accepted standard of 10%.
August 16, 2019
The FDA-approved use of TAVR has now expanded to low-risk patients with severe aortic stenosis. This includes both Edwards Lifesciences' Sapien 3 and Sapien 3 Ultra as well as Medtronic's Evolut R and Evolut PRO.
Early Migration of a Self-Expanding Transcatheter Aortic Valve Prosthesis Causing Coronary Occlusion: A Practical Technique for Surgical Explantation
July 24, 2019
The authors report a case of early migration of a self-expanding transcatheter aortic valve prosthesis causing coronary obstruction and myocardial infarction.
Transcatheter Valve-in-Valve Versus Surgical Replacement of Failing Stented Aortic Biological Valves
July 20, 2019
This retrospective study by Sedeek et al aimed to compare the outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) valve-in-valve (n=90) versus surgical replacement (SAVR) (n=260) of failing stented aortic biological valves in a cohort of 350 patients .
July 19, 2019
Patient Care and General Interest
Feasibility of Repeat TAVR After SAPIEN 3 TAVR: A Novel Classification Scheme and Pilot Angiographic Study
July 9, 2019
Transcatheter aortic valve replacement (TAVR) is expanding to younger patients, but the feasibility of TAVR in failing transcatheter aortic valves (TAV) remains unknown.